Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes

Inclusion Criteria A subject is eligible for the study if all of the following criteria are met: * Provide written informed consent prior to enrollment. * Is male or female between 18-70 years old. * Has been diagnosed with type II diabetes for greater than 12 months. * Is currently either using lifestyle modification or taking one or two of the following oral antihyperglycemic agents and has been on stable doses for 90 days prior to screening: * metformin * DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, linaglyptin) * Pioglitazone * Has an A l c between 7.5 - 9.0% based upon point of care testing performed at visit 1. * Currently performs self-monitoring blood glucose checks at least 3 times per week. * Able to adhere to protocol requirements. Exclusion Criteria A subject will be excluded if any of the following criteria are met: * Has Type 1 Diabetes or Gestational Diabetes. * Is pregnant or planning to become pregnant during the course of the study. * Current use OR use in the past 6 months of sulfonylureas. * Current use OR use in the past 6 months of insulin * History of cardiovascular disease or cerebrovascular disease. * Any planned surgery during the course of the study. * Current continuous renal replacement therapy. * Current oral or injectable steroid use or use within the previous 3 months. * Previous or current treatment with deep brain stimulation. * Any previous known disease, injury, or surgical intervention involving the brain or central nervous system. * Moderate or greater hearing loss. * Presence of a cochlear implant. * Diagnosed vestibular dysfunction. * Eye surgery within the previous three months. * Any history of previous ear surgery. * Active ear infections or a perforated tympanic membrane. * Presence of a serious or unstable medical or psychological condition which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.